LD-2 disclosure · 4th Quarter - Termination

COHERUS BIOSCIENCES

4th Quarter (Oct 1 - Dec 31) · 2023Posted Dec 31, 2023Filing document ↗LDA record ↗

Income$50Kfee reported

Client

1 issue

Pharmacy
S. 3311 - American Made Pharmaceuticals Act of 2023 - Support for policies that encourage keeping the different elements of the prescription drug supply chain in the country to support better access to lifesaving medications and expand the number of quality jobs in the United States. Issues related to drug shortages in the United States and the role biosimilars can play. Issues related to cancer care and developing both biosimilar and novel treatments to fight disease. Issues related to advancing biosimilars in the health care market place to increase access and efficacy of life saving drugs. Support for encouraging the development, manufacturing and distribution of American-made biosimilars and other related products.
Lobbyistsms MELANIE JAN NATHANSON · ms MEGAN HAUCK MARSHALL
TargetedSENATE · HOUSE OF REPRESENTATIVES

LD-2 disclosure · 4th Quarter - Termination

4th Quarter (Oct 1 - Dec 31) · 2023Posted Dec 31, 2023Filing document ↗LDA record ↗

Income$50Kfee reported

1 issue

Pharmacy
S. 3311 - American Made Pharmaceuticals Act of 2023 - Support for policies that encourage keeping the different elements of the prescription drug supply chain in the country to support better access to lifesaving medications and expand the number of quality jobs in the United States. Issues related to drug shortages in the United States and the role biosimilars can play. Issues related to cancer care and developing both biosimilar and novel treatments to fight disease. Issues related to advancing biosimilars in the health care market place to increase access and efficacy of life saving drugs. Support for encouraging the development, manufacturing and distribution of American-made biosimilars and other related products.
Lobbyistsms MELANIE JAN NATHANSON · ms MEGAN HAUCK MARSHALL
TargetedSENATE · HOUSE OF REPRESENTATIVES